Oncotarget

Research Papers:

Androgen receptor CAG and GGN repeat length variation contributes more to the tumorigenesis of osteosarcoma

Yongxiang Shi, Weishan Chen, Qinghuai Li, Zhaoming Ye _

PDF |  HTML  |  Order a Reprint  |  This article has been retracted. Oncotarget. 2017; 8:34019.

Oncotarget. 2016; 7:68151-68155. https://doi.org/10.18632/oncotarget.11902

Metrics: PDF 449 views  |   HTML 564 views  |   ?  


Abstract

Yongxiang Shi1, Weishan Chen1, Qinghuai Li2, Zhaoming Ye1

1Department of Orthopaedic Surgery, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

2Department of Medicine, 3rd Hospital of Henan Province, Henan, China

Correspondence to:

Zhaoming Ye, email: ye_zhaoming@163.com

Keywords: osteosarcoma, papillary thyroid cancer, AR, repeat, CAG

Received: May 24, 2016     Accepted: August 13, 2016     Published: September 08, 2016

ABSTRACT

The androgen receptor (AR) is involved in the differentiation and growth of many cancers. We hypothesized that two microsatellite polymorphic variants, AR (CAG)n and (GGN)n repeats, were also associated with the development of Papillary thyroid cancer (PTC) and Osteosarcoma. In current study, we conducted two case-control studies in a Chinese population to investigate the possible relationship between these two AR repeat polymorphisms and the risk of PTC and Osteosarcoma. The AR CAG repeat length was significantly associated with both risk of PTC and Osteosarcoma. Subjects with shorter AR CAG repeats had a higher risk of developing PTC (OR = 1.47, 95% CI: 1.17–1.85, P = 0.001) and Osteosarcoma (OR = 1.53, 95% CI: 1.19–1.97, P = 9.2 x 10–4). Specifically, shorter GGN repeats also contribute a significant increased risk of Osteosarcoma (OR = 1.35, 95% CI: 1.03–1.77, P = 0.030). Our results contribute to a better understanding of the complex hormone related mechanisms underlying PTC and Osteosarcoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11902